Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
Global single-use technologies for the biologic market was valued at USD 4.79 billion in 2024 and is projected to grow to USD 9.59 billion by 2031, registering a CAGR of 10.7% during the forecast period. This robust growth reflects increasing adoption across biopharmaceutical manufacturing due to efficiency and cost advantages.
Single-use technologies (SUT) refer to disposable solutions including bioreactors, filtration systems, and tubing designed for one-time applications in biopharmaceutical production. These systems eliminate cross-contamination risks while reducing facility footprint and cleaning validation burdens. Key product segments encompass membrane adsorbers, bioreactors, disposable mixing systems, and tangential flow filtration devices.
The market expansion is driven by rising demand for biologics, particularly monoclonal antibodies and vaccines, which accounted for over 60% of segment revenue in 2024. While conventional stainless-steel systems dominated historically, pandemic-induced scalability needs accelerated SUT adoption. However, material compatibility concerns and limited large-scale application above 2000L remain industry challenges. Strategic partnerships among key players like Thermo Fisher Scientific and Sartorius aim to address these limitations through advanced polymer innovations.
Biopharmaceutical Industry Growth
The global biopharmaceutical market is projected to grow at a CAGR of 8.4% through 2030, driving increased demand for single-use technologies. Biologic drug development requires flexible manufacturing solutions, making single-use systems ideal for rapid scale-up and multiproduct facilities.
Cost Efficiency and Operational Benefits
Single-use technologies reduce capital expenditures by 30-40% compared to traditional stainless steel systems. Elimination of cleaning validation and reduced contamination risks make them particularly attractive for biologic manufacturing.
Over 70% of new biomanufacturing facilities now incorporate single-use technologies for at least part of their production workflow
The COVID-19 pandemic accelerated adoption, proving the agility of single-use systems for vaccine production and reinforcing their position in biologic manufacturing.
MARKET CHALLENGES
Scalability Limitations
While ideal for clinical-scale production, some single-use technologies face challenges in large-scale commercial manufacturing of biologics, particularly for blockbuster drugs requiring multi-ton annual production.
Other Challenges
Supply Chain Vulnerabilities
Dependence on limited suppliers for critical components creates potential bottlenecks in biologics production timelines.
Leachables and Extractables
Meeting stringent regulatory requirements for biologic products remains a technical challenge for single-use systems.
High Initial Investment Costs
While operational costs are lower, the premium pricing of single-use bioreactors and other components presents a barrier to adoption for some biologic manufacturers. The average cost for a single-use bioreactor system ranges from $250,000 to $500,000 depending on scale.
Modular and Flexible Biomanufacturing
The shift toward modular facilities and continuous bioprocessing represents a $1.2 billion opportunity for single-use technology providers. Personalized medicine and small-batch biologics production are particularly well-suited to these systems.
Emerging Markets Expansion
Asia-Pacific biopharmaceutical companies are increasingly adopting single-use technologies, with the region expected to account for 35% of global demand by 2026. Local manufacturing initiatives for biosimilars and vaccines are driving this growth.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Bioreactors dominate the single-use technology segment due to their extensive use in biologic production processes. These systems offer significant advantages in contamination control and operational flexibility compared to traditional stainless steel bioreactors. Membrane adsorbers are gaining traction for their efficiency in downstream purification processes, while disposable mixing systems are valued for their ease of use in buffer preparation. |
| By Application |
|
Monoclonal Antibodies represent the most substantial application area for single-use technologies, driven by the increasing demand for targeted biologic therapies. The vaccine segment is experiencing rapid adoption of disposable systems due to the need for flexible manufacturing during pandemic responses. Gene therapy applications show particularly strong growth potential as these advanced therapies move toward commercialization at scale. |
| By End User |
|
Contract Manufacturing Organizations are leading adopters of single-use technologies due to the flexibility these systems provide in handling multiple products in shared facilities. Large pharmaceutical companies are increasingly incorporating disposable technologies into their facility designs to reduce validation requirements and accelerate time-to-market. Biotechnology startups favor single-use systems for their lower capital investment requirements compared to traditional stainless steel installations. |
| By Technology Adoption Level |
|
Mainstream Users currently represent the largest segment as single-use technologies become standard practice in biologic manufacturing. Early adopters continue to push boundaries with complete single-use production trains, while late adopters are gradually transitioning from stainless steel systems as they recognize the operational and cost benefits. The technology adoption curve reflects wider industry acceptance of disposable solutions in GMP manufacturing. |
| By System Integration |
|
Complete Single-Use Trains are emerging as the preferred configuration for new facilities, offering end-to-end production capabilities with minimum intervention points. While standalone components still dominate retrofit applications, intermediate integration solutions are gaining popularity for their balance between flexibility and standardization. The industry is moving toward more sophisticated single-use system architectures that incorporate advanced automation and monitoring capabilities. |
Global Single-Use Technologies for Biologics Market Dominated by Established Pharma Solutions Providers
The single-use technologies for biologics market is highly consolidated, with Thermo Fisher Scientific and Sartorius leading through comprehensive product portfolios and global distribution networks. These companies hold approximately 30% combined market share through their advanced single-use bioreactors, filtration systems, and consumables. The market structure reflects strategic acquisitions, with major players expanding capabilities through M&A activities in niche technology segments.
Specialized providers like Pall Corporation and EMD Millipore maintain strong positions in filtration technologies, while Applikon Biotechnology focuses on innovative single-use bioreactor designs. Emerging players are gaining traction in regional markets through cost-effective alternatives and application-specific solutions, particularly in Asia-Pacific biomanufacturing hubs.
List of Key Single-Use Technologies for Biologics Companies ProfiledGE Healthcare
Merck Millipore
Applikon Biotechnology
BioPure Technology
Novasep
W. L. Gore and Associates
Meissner Filtration Products
Saint-Gobain
Repligen Corporation
The global Single-Use Technologies for Biologics market reached $4.8 billion in 2024 and is projected to grow at 10.7% CAGR through 2031, reaching $9.6 billion. This growth is primarily fueled by increasing production of monoclonal antibodies, vaccines, and gene therapies. The adoption of single-use systems reduces contamination risks and facility footprint while improving operational efficiency in biomanufacturing.
Other TrendsProduct Type Segmentation Growth
Membrane adsorbers and single-use bioreactors account for the largest product segments, with bioreactors showing the fastest growth at 12.3% CAGR due to increasing vaccine production demands. Disposable mixing systems and tangential flow filtration units are gaining traction for buffer preparation and purification processes.
Regional Market DevelopmentsNorth America currently leads with 38% market share due to strong biopharmaceutical R&D infrastructure, while Asia-Pacific shows the highest growth potential at 13.2% CAGR, driven by expanding biologics manufacturing in China and India. Europe maintains steady growth with increasing adoption of single-use systems for biosimilar production.
Competitive Landscape Shifts
The market remains consolidated with Thermo Fisher Scientific, Sartorius, and Merck Millipore dominating over 60% of total revenue. Recent acquisitions focus on expanding product portfolios in tubing assemblies and connector technologies. Emerging players are targeting niche applications in cell and gene therapy single-use solutions.
Regulatory and Sustainability ChallengesWhile regulatory acceptance of single-use technologies has improved, extractables/leachables testing remains a key consideration. The industry is responding with improved material science developments. Sustainability concerns about plastic waste are driving innovation in biodegradable polymer materials for disposable components.
Regional Analysis: Single-Use Technologies for the Biologic MarketEurope
Europe represents the second-largest market for single-use bioprocessing technologies, characterized by strong environmental regulations favoring disposable systems. The EMA's harmonized approach to single-use technology validation has created a stable adoption environment. Key markets like Germany, Switzerland, and the UK host numerous single-use technology innovators tailoring solutions for complex biologics. European manufacturers emphasize sustainability aspects, driving development of recyclable single-use components. The region shows particular strength in single-use systems for vaccine production, with several large-scale facilities transitioning to hybrid disposable models. Academic-industry collaborations in countries like Sweden are advancing single-use applications for continuous bioprocessing of biologics.
Asia-Pacific
Asia-Pacific is the fastest-growing region for single-use biologic technologies, led by expanding biopharmaceutical production in China and South Korea. Governments are actively supporting local single-use technology development to reduce reliance on imports. The region benefits from lower labor costs that offset some disposable system advantages, but adoption grows for high-value biologics. Japan maintains leadership in single-use validation technologies, while India emerges as a hub for cost-effective single-use solutions. Regional differences in regulatory expectations create market fragmentation, though harmonization efforts are underway. Local manufacturers increasingly adopt single-use technologies for biosimilars and niche biologic products.
South America
South America shows nascent but promising growth in single-use biologics technologies, primarily driven by vaccine manufacturing needs. Brazil leads regional adoption with government initiatives supporting local bioproduction capabilities. Challenges include limited local suppliers and higher technology import costs. Single-use adoption focuses on smaller-scale biologic production where capital expenditure constraints make disposable systems attractive. The region shows particular interest in single-use technologies for pandemic preparedness and public health biologics, with several countries establishing strategic stockpiles of disposable manufacturing capacity.
Middle East & Africa
The MEA region exhibits gradual single-use technology adoption concentrated in biopharmaceutical hubs like Saudi Arabia and South Africa. Government investments in biotechnology infrastructure are creating opportunities for disposable system implementation. The region's focus on vaccine sovereignty and specialty biologic production drives interest in modular single-use facilities. Challenges include limited technical expertise and reliance on international suppliers. Strategic partnerships with global single-use technology providers are helping bridge capability gaps for localized biologics manufacturing.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Biopharmaceutical companies
Medical technology manufacturers
Contract research organizations
Healthcare investors and analysts
Regulatory and policy makers
-> Global single-use technologies for the biologic market was valued at USD 4.79 billion in 2024 and is projected to reach USD 9.59 billion by 2031.
Which key companies operate in Global Single-Use Technologies for the Biologic Market?
-> Key players include Thermo Fisher Scientific, Sartorius, GE Healthcare, Pall, and EMD Millipore, among others.
-> Key growth drivers include rising demand for biologics, pandemic-induced scalability needs, and cost efficiency advantages.
-> North America currently leads the market, while Asia-Pacific shows the highest growth potential.
-> Emerging trends include advanced polymer innovations, larger-capacity disposable systems, and hybrid bioprocessing solutions.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates